Loading…
Loading…
SRNE does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SRNE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SRNE and 80,000+ other tickers.
See exactly how SRNE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SRNE and 80,000+ other tickers.
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex. A core focus lies in cancer therapeutics, where Sorrento harnesses its proprietary G-MAB antibody library. This is complemented by advanced, targeted delivery systems such as chimeric antigen…
Sorrento Voyage has announced the expansion of its private boat tours and romantic proposal experiences across the Amalfi Coast and Capri, offering travelers personalized sea-based journeys led by its founding team. Sorrento, Italy--(Newsfile Corp. - January 5, 2026) - Sorrento Voyage, a private charter company based in Piano di Sorrento, has expanded its range of bespoke luxury boat tours and romantic experiences along the Amalfi Coast, responding to growing demand for intimate, experience-led travel in Southern Italy.
Institutional and Insider Ownership 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money
Institutional and Insider Ownership 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments
Earnings and Valuation This table compares Sorrento Therapeutics and its rivals revenue, earnings per share and valuation. Gross Revenue Net Income Price/Earnings Ratio Sorrento Therapeutics $62.84 million -$572.84 million -0.01 Sorrento Therapeutics Competitors $41.99 million -$89.56 million -5.51 Sorrento Therapeutics has higher revenue, but lower earnings than its rivals. Sorrento Therapeutics is trading at a
Valuation and Earnings This table compares Sorrento Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Net Income Price/Earnings Ratio Sorrento Therapeutics $62.84 million -$572.84 million -0.01 Sorrento Therapeutics Competitors $41.99 million -$89.56 million -5.73 Sorrento Therapeutics has higher revenue, but lower earnings than its peers. Sorrento Therapeutics is trading